Prescription drug · BLA
Selarsdi (Ustekinumab-aekn) NDC 50090-7769
Ustekinumab 90 mg/mL · Injection, Solution · Subcutaneous · A-S Medication Solutions
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 50090-7769-0 | 5009077690050090776900 | 1 TRAY in 1 CARTON (50090-7769-0) / 1 mL in 1 TRAYMarketed from Nov 17, 2025 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Selarsdi
- Generic name (nonproprietary)
- ustekinumab-aekn
- Active ingredients
- Ustekinumab — 90 mg/mL
- Dosage form
- Injection, Solution
- Route
- Subcutaneous
- Labeler
- A-S Medication SolutionsNDC labeler code 50090
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 761343
- Marketing start
- Listing expires
- Other FDA classes
- Interleukin-12 Antagonists (Mechanism)Interleukin-23 Antagonists (Mechanism)
- Identifiers
- Product ID 50090-7769_81578a89-3268-4b46-8cf7-79af3145f247SPL ID 81578a89-3268-4b46-8cf7-79af3145f247SPL set ID b3b483f4-3426-4d6d-97ae-39848ec1bfaeRxCUI 2705400, 2705401UNII FU77B4U5Z0
- Pharmacologic class
- Interleukin-12 Antagonist; Interleukin-23 Antagonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeMed-Code curated
J3357 — Injection, ustekinumab, for subcutaneous injection, 1 mg
Billing unit: 1 mg. Units on the claim = dose given ÷ 1 mg.
J3357 covers the subcutaneous formulation. The intravenous formulation has a separate code (J3358). Ustekinumab biosimilars are listed under their own names.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N450090776900followed by a unit qualifier and the quantityPackage 50090-7769-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
SELARSDI is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) moderately to severely active Crohn’s disease (CD). ( 1.3 ) moderately to severely active ulcerative colitis. ( 1.4 ) Pediatric patients 6 years and older with: moderate to severe plaque psoriasis, who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) 1.1 Plaque Psoriasis (PsO) SELARSDI™ is indicated for the treatment of adults and pediatric patients 6 years of age and older with modera…
Excerpt only. Read the full label for complete information.
About NDC 50090-7769
- What is NDC 50090-7769?
- 50090-7769 is the product NDC for Selarsdi (ustekinumab-aekn), Ustekinumab 90 mg/mL injection, solution, listed with the FDA by A-S Medication Solutions. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Selarsdi (Ustekinumab-aekn).
- What is the active ingredient?
- Ustekinumab.
- Who is the labeler?
- A-S Medication Solutions, NDC labeler code 50090. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Selarsdi?
- 3 other product NDCs are listed under this name. See all Selarsdi NDCs.
- Is there a related HCPCS / J-code?
- Yes: J3357, Injection, ustekinumab, for subcutaneous injection, 1 mg. See Billing references above.
Related NDCs: other Selarsdi products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Selarsdiustekinumab-aekn | Ustekinumab-aekn 45 mg/.5mL | Injection, SolutionSubcutaneous | Teva Pharmaceuticals USA, Inc. | 51759-505 | 51759-0505-1351759-0505-32 |
| Selarsdiustekinumab-aekn | Ustekinumab-aekn 90 mg/mL | Injection, SolutionSubcutaneous | Teva Pharmaceuticals USA, Inc. | 51759-607 | 51759-0607-32 |
| Selarsdiustekinumab-aekn | Ustekinumab-aekn 130 mg/26mL | Injection, SolutionIntravenous | Teva Pharmaceuticals USA, Inc. | 51759-708 | 51759-0708-13 |
Other NDCs under BLA 761343
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Selarsdiustekinumab-aekn | Ustekinumab-aekn 45 mg/.5mL | Injection, SolutionSubcutaneous | Teva Pharmaceuticals USA, Inc. | 51759-505 |
| Selarsdiustekinumab-aekn | Ustekinumab-aekn 90 mg/mL | Injection, SolutionSubcutaneous | Teva Pharmaceuticals USA, Inc. | 51759-607 |
| Selarsdiustekinumab-aekn | Ustekinumab-aekn 130 mg/26mL | Injection, SolutionIntravenous | Teva Pharmaceuticals USA, Inc. | 51759-708 |
| Ustekinumab-aekn | Ustekinumab-aekn 45 mg/.5mL | Injection, SolutionSubcutaneous | Teva Pharmaceuticals USA, Inc. | 51759-413 |
| Ustekinumab-aekn | Ustekinumab-aekn 90 mg/mL | Injection, SolutionSubcutaneous | Teva Pharmaceuticals USA, Inc. | 51759-414 |
| Ustekinumab-aekn | Ustekinumab-aekn 45 mg/.5mL | Injection, SolutionSubcutaneous | Teva Pharmaceuticals USA, Inc. | 51759-709 |
| Ustekinumab-aekn | Ustekinumab-aekn 90 mg/mL | Injection, SolutionSubcutaneous | Teva Pharmaceuticals USA, Inc. | 51759-710 |